|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
The outbreak of corona virus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is currently the peak season of common respiratory viral infections. Influenza A was one of the most common respiratory viruses, which may have caused initial false negative results of real-time reverse-transcriptase polymerase chain reaction for severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) among the SARI patients. In contrast, clinicians cannot rule out SARS-CoV-2 and Influenza infection based on the clinical and laboratory findings. Therefore, clinicians must have a high index of suspicion for coinfection among COVID-19 patients. After recognizing the possible pathogens causing co-infection among COVID-19 patients, appropriate antimicrobial agents can be recommended. A total of 104 SARI patients with clinically suspected of COVID-19 in a tertiary care hospital Thanjavur were recruited from December 2020 to February 2021. Nasopharyngeal swabs, throat swabs were collected to detect SARS-CoV-2 and Influenza A virus by using real-time reverse transcription-polymerase chain reaction (RT-PCR). Clinical characteristics and laboratory test findings were acquired from medical records. All data were analysed to recognize the epidemiological patterns. Among the 104 SARI patients, 25.6%(27/104) patients with suspected COVID-19 were eventually confirmed to have SARS-CoV-2 infection, and the most frequently observed symptoms were cough (86%, 90/104) followed by Fever (84%, 88/104), breathlessness (80%,83/104), myalgia (25%,27/104), vomiting (15.3%,16/104), diarrhoea (12.5%13/104), chest pain (10.5%,11/104). There were no cases out of 104 SARI patients who were positive for Influenza (H1N1) by RT-PCR.